Recurrent Pericarditis: A Promising Future for IL-1 Blockers in Autoinflammatory Phenotypes
- PMID: 37380302
- DOI: 10.1016/j.jacc.2023.05.013
Recurrent Pericarditis: A Promising Future for IL-1 Blockers in Autoinflammatory Phenotypes
Keywords: IL-1 antagonists; IL-1 blockers; acute pericarditis; autoinflammatory pericarditis; recurrent pericarditis; treatment.
Conflict of interest statement
Funding Support and Author Disclosures Dr Klein has received research funding from Kiniksa Pharmaceuticals; and has served on scientific advisory boards for Kiniksa Pharmaceuticals, Cardiol Therapeutics, Pfizer, and Sobi Pharmaceuticals. Dr Cremer has received grants from Novartis Pharmaceuticals and Kiniksa Pharmaceuticals; and has served on scientific advisory boards for Sobi Pharmaceuticals and Kiniksa Pharmaceuticals. Dr Kafil has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Treatment of Idiopathic Recurrent Pericarditis With Goflikicept: Phase II/III Study Results.J Am Coll Cardiol. 2023 Jul 4;82(1):30-40. doi: 10.1016/j.jacc.2023.04.046. J Am Coll Cardiol. 2023. PMID: 37380301 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources